Global Orthobiologics Market

Orthobiologics Comprehensive Study by Type (Viscosupplementation Products, DBM, Synthetic Orthobiologics, BMP, Allografts, PRP, BMAC), Application (Fracture Recovery, Spinal Fusion, Soft Tissue Injuries, Osteoarthritis and Degenerative Arthritis), End User (Hospitals) Players and Region - Global Market Outlook to 2030

Orthobiologics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Orthobiologics Market Scope
Orthobiologics, also called regenerative cellular therapies, is an advancing medical field that involves the use of biomaterials and cell-based therapies to repair broken bones, prevent bone degeneration, and provide bone stability. Orthobiologic products are obtained from naturally occurring materials. These products help treat people with long-term disabling musculoskeletal disorders and injuries. In the current scenario, emerging technological innovations in biomaterials, used in the production of orthobiologics are emerging out as a lucrative opportunity for the market growth



Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Orthobiologics market throughout the predicted period.

DePuy Synthes (Johnson & Johnson) (United States), Medtronic (Ireland), Sanofi S.A (France), Stryker (United States), Zimmer Biomet (United States), Alphatec Spine Inc. (United States), AlloSource (United States), SINTX Technologies Inc. (United States), Anika Therapeutics (United States), Arthrex Inc. (United States), Baxter (United States), BBS-Bioactive Bone Substitutes (Finland), Berkeley Advanced Biomaterial (United States), Wright Medical Group Inc. (United States), Bioventus (United States), Bone Therapeutics (Belgium), Ceramisys (United Kingdom) and Geistlich Bio-Oss (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Graftys (France), Integra Life Sciences (United States), ISTO Technologies (United States), NovaBone Products LLC (United States), Orthogem (United Kingdom), Orthofix Holdings Inc. (United States), OsteoMed (United States), RTI Surgical (United States), Smith & Nephew (United Kingdom) and Xtant Medical (United States).

Segmentation Overview
The study have segmented the market of Global Orthobiologics market by Type (Viscosupplementation Products, DBM, Synthetic Orthobiologics, BMP, Allografts, PRP and BMAC), by Application (Fracture Recovery, Spinal Fusion, Soft Tissue Injuries and Osteoarthritis and Degenerative Arthritis) and Region with country level break-up.

On the basis of geography, the market of Orthobiologics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Growing Patient Preference for Minimally Invasive Procedures

Market Growth Drivers:
Increasing Incidence of Sports Injuries and Road Accidents, Surging Incidence of Spinal Diseases/Disorders and Rising Geriatric and Obese Population

Challenges:
Lawsuits Filed Against Major Market Players Affecting Their Brand Value and Side Effects Associated With Bmp-Based Treatments

Restraints:
High Cost Associated With Orthobiologics-Based Treatments

Opportunities:
Increasing Awareness of Orthobiologics and Rise in Demand for Advanced Treatment

Market Leaders and their Expansionary Development Strategies
In February 2019, Orthofix Medical Inc., a global medical device company focused on musculoskeletal products and therapies, announced that it has acquired the business of Options Medical, LLC, a medical device distributor based in Florida
In March 2019, AlloSource, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, announced that it has enrolled the first patient in a study titled A Prospective, Multi-Center Study Evaluating ProChondrix® CR for the Repair of Focal Articular Cartilage Defects in the Knee. and In January 2019, Bioventus, launched OSTEOMATRIX+, next-generation biphasic bone graft for use in bone remodeling in a variety of orthopaedic and spine applications


Key Target Audience
Orthobiologics Product Manufacturing Companies, Product Suppliers, Distributors, and Channel Partners, Hospitals and Ambulatory Care Centers, Orthopedic and Dental Clinics, Research Laboratories and CROs, Research and Academic Institutes, National and International Regulatory Authorities and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Type
  • Viscosupplementation Products
  • DBM
  • Synthetic Orthobiologics
  • BMP
  • Allografts
  • PRP
  • BMAC
By Application
  • Fracture Recovery
  • Spinal Fusion
  • Soft Tissue Injuries
  • Osteoarthritis and Degenerative Arthritis
By End User
  • Hospitals

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence of Sports Injuries and Road Accidents
      • 3.2.2. Surging Incidence of Spinal Diseases/Disorders
      • 3.2.3. Rising Geriatric and Obese Population
    • 3.3. Market Challenges
      • 3.3.1. Lawsuits Filed Against Major Market Players Affecting Their Brand Value
      • 3.3.2. Side Effects Associated With Bmp-Based Treatments
    • 3.4. Market Trends
      • 3.4.1. Growing Patient Preference for Minimally Invasive Procedures
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Orthobiologics, by Type, Application, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Orthobiologics (Value)
      • 5.2.1. Global Orthobiologics by: Type (Value)
        • 5.2.1.1. Viscosupplementation Products
        • 5.2.1.2. DBM
        • 5.2.1.3. Synthetic Orthobiologics
        • 5.2.1.4. BMP
        • 5.2.1.5. Allografts
        • 5.2.1.6. PRP
        • 5.2.1.7. BMAC
      • 5.2.2. Global Orthobiologics by: Application (Value)
        • 5.2.2.1. Fracture Recovery
        • 5.2.2.2. Spinal Fusion
        • 5.2.2.3. Soft Tissue Injuries
        • 5.2.2.4. Osteoarthritis and Degenerative Arthritis
      • 5.2.3. Global Orthobiologics by: End User (Value)
        • 5.2.3.1. Hospitals
      • 5.2.4. Global Orthobiologics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Orthobiologics (Price)
      • 5.3.1. Global Orthobiologics by: Type (Price)
  • 6. Orthobiologics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. DePuy Synthes (Johnson & Johnson) (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Medtronic (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi S.A (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Stryker (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Zimmer Biomet (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Alphatec Spine Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AlloSource (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. SINTX Technologies Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Anika Therapeutics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Arthrex Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Baxter (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. BBS-Bioactive Bone Substitutes (Finland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Berkeley Advanced Biomaterial (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Wright Medical Group Inc. (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Bioventus (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Bone Therapeutics (Belgium)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Ceramisys (United Kingdom)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
      • 6.4.18. Geistlich Bio-Oss (United States)
        • 6.4.18.1. Business Overview
        • 6.4.18.2. Products/Services Offerings
        • 6.4.18.3. Financial Analysis
        • 6.4.18.4. SWOT Analysis
  • 7. Global Orthobiologics Sale, by Type, Application, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Orthobiologics (Value)
      • 7.2.1. Global Orthobiologics by: Type (Value)
        • 7.2.1.1. Viscosupplementation Products
        • 7.2.1.2. DBM
        • 7.2.1.3. Synthetic Orthobiologics
        • 7.2.1.4. BMP
        • 7.2.1.5. Allografts
        • 7.2.1.6. PRP
        • 7.2.1.7. BMAC
      • 7.2.2. Global Orthobiologics by: Application (Value)
        • 7.2.2.1. Fracture Recovery
        • 7.2.2.2. Spinal Fusion
        • 7.2.2.3. Soft Tissue Injuries
        • 7.2.2.4. Osteoarthritis and Degenerative Arthritis
      • 7.2.3. Global Orthobiologics by: End User (Value)
        • 7.2.3.1. Hospitals
      • 7.2.4. Global Orthobiologics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Orthobiologics (Price)
      • 7.3.1. Global Orthobiologics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Orthobiologics: by Type(USD Billion)
  • Table 2. Orthobiologics Viscosupplementation Products , by Region USD Billion (2018-2023)
  • Table 3. Orthobiologics DBM , by Region USD Billion (2018-2023)
  • Table 4. Orthobiologics Synthetic Orthobiologics , by Region USD Billion (2018-2023)
  • Table 5. Orthobiologics BMP , by Region USD Billion (2018-2023)
  • Table 6. Orthobiologics Allografts , by Region USD Billion (2018-2023)
  • Table 7. Orthobiologics PRP , by Region USD Billion (2018-2023)
  • Table 8. Orthobiologics BMAC , by Region USD Billion (2018-2023)
  • Table 9. Orthobiologics: by Application(USD Billion)
  • Table 10. Orthobiologics Fracture Recovery , by Region USD Billion (2018-2023)
  • Table 11. Orthobiologics Spinal Fusion , by Region USD Billion (2018-2023)
  • Table 12. Orthobiologics Soft Tissue Injuries , by Region USD Billion (2018-2023)
  • Table 13. Orthobiologics Osteoarthritis and Degenerative Arthritis , by Region USD Billion (2018-2023)
  • Table 14. Orthobiologics: by End User(USD Billion)
  • Table 15. Orthobiologics Hospitals , by Region USD Billion (2018-2023)
  • Table 16. South America Orthobiologics, by Country USD Billion (2018-2023)
  • Table 17. South America Orthobiologics, by Type USD Billion (2018-2023)
  • Table 18. South America Orthobiologics, by Application USD Billion (2018-2023)
  • Table 19. South America Orthobiologics, by End User USD Billion (2018-2023)
  • Table 20. Brazil Orthobiologics, by Type USD Billion (2018-2023)
  • Table 21. Brazil Orthobiologics, by Application USD Billion (2018-2023)
  • Table 22. Brazil Orthobiologics, by End User USD Billion (2018-2023)
  • Table 23. Argentina Orthobiologics, by Type USD Billion (2018-2023)
  • Table 24. Argentina Orthobiologics, by Application USD Billion (2018-2023)
  • Table 25. Argentina Orthobiologics, by End User USD Billion (2018-2023)
  • Table 26. Rest of South America Orthobiologics, by Type USD Billion (2018-2023)
  • Table 27. Rest of South America Orthobiologics, by Application USD Billion (2018-2023)
  • Table 28. Rest of South America Orthobiologics, by End User USD Billion (2018-2023)
  • Table 29. Asia Pacific Orthobiologics, by Country USD Billion (2018-2023)
  • Table 30. Asia Pacific Orthobiologics, by Type USD Billion (2018-2023)
  • Table 31. Asia Pacific Orthobiologics, by Application USD Billion (2018-2023)
  • Table 32. Asia Pacific Orthobiologics, by End User USD Billion (2018-2023)
  • Table 33. China Orthobiologics, by Type USD Billion (2018-2023)
  • Table 34. China Orthobiologics, by Application USD Billion (2018-2023)
  • Table 35. China Orthobiologics, by End User USD Billion (2018-2023)
  • Table 36. Japan Orthobiologics, by Type USD Billion (2018-2023)
  • Table 37. Japan Orthobiologics, by Application USD Billion (2018-2023)
  • Table 38. Japan Orthobiologics, by End User USD Billion (2018-2023)
  • Table 39. India Orthobiologics, by Type USD Billion (2018-2023)
  • Table 40. India Orthobiologics, by Application USD Billion (2018-2023)
  • Table 41. India Orthobiologics, by End User USD Billion (2018-2023)
  • Table 42. South Korea Orthobiologics, by Type USD Billion (2018-2023)
  • Table 43. South Korea Orthobiologics, by Application USD Billion (2018-2023)
  • Table 44. South Korea Orthobiologics, by End User USD Billion (2018-2023)
  • Table 45. Taiwan Orthobiologics, by Type USD Billion (2018-2023)
  • Table 46. Taiwan Orthobiologics, by Application USD Billion (2018-2023)
  • Table 47. Taiwan Orthobiologics, by End User USD Billion (2018-2023)
  • Table 48. Australia Orthobiologics, by Type USD Billion (2018-2023)
  • Table 49. Australia Orthobiologics, by Application USD Billion (2018-2023)
  • Table 50. Australia Orthobiologics, by End User USD Billion (2018-2023)
  • Table 51. Rest of Asia-Pacific Orthobiologics, by Type USD Billion (2018-2023)
  • Table 52. Rest of Asia-Pacific Orthobiologics, by Application USD Billion (2018-2023)
  • Table 53. Rest of Asia-Pacific Orthobiologics, by End User USD Billion (2018-2023)
  • Table 54. Europe Orthobiologics, by Country USD Billion (2018-2023)
  • Table 55. Europe Orthobiologics, by Type USD Billion (2018-2023)
  • Table 56. Europe Orthobiologics, by Application USD Billion (2018-2023)
  • Table 57. Europe Orthobiologics, by End User USD Billion (2018-2023)
  • Table 58. Germany Orthobiologics, by Type USD Billion (2018-2023)
  • Table 59. Germany Orthobiologics, by Application USD Billion (2018-2023)
  • Table 60. Germany Orthobiologics, by End User USD Billion (2018-2023)
  • Table 61. France Orthobiologics, by Type USD Billion (2018-2023)
  • Table 62. France Orthobiologics, by Application USD Billion (2018-2023)
  • Table 63. France Orthobiologics, by End User USD Billion (2018-2023)
  • Table 64. Italy Orthobiologics, by Type USD Billion (2018-2023)
  • Table 65. Italy Orthobiologics, by Application USD Billion (2018-2023)
  • Table 66. Italy Orthobiologics, by End User USD Billion (2018-2023)
  • Table 67. United Kingdom Orthobiologics, by Type USD Billion (2018-2023)
  • Table 68. United Kingdom Orthobiologics, by Application USD Billion (2018-2023)
  • Table 69. United Kingdom Orthobiologics, by End User USD Billion (2018-2023)
  • Table 70. Netherlands Orthobiologics, by Type USD Billion (2018-2023)
  • Table 71. Netherlands Orthobiologics, by Application USD Billion (2018-2023)
  • Table 72. Netherlands Orthobiologics, by End User USD Billion (2018-2023)
  • Table 73. Rest of Europe Orthobiologics, by Type USD Billion (2018-2023)
  • Table 74. Rest of Europe Orthobiologics, by Application USD Billion (2018-2023)
  • Table 75. Rest of Europe Orthobiologics, by End User USD Billion (2018-2023)
  • Table 76. MEA Orthobiologics, by Country USD Billion (2018-2023)
  • Table 77. MEA Orthobiologics, by Type USD Billion (2018-2023)
  • Table 78. MEA Orthobiologics, by Application USD Billion (2018-2023)
  • Table 79. MEA Orthobiologics, by End User USD Billion (2018-2023)
  • Table 80. Middle East Orthobiologics, by Type USD Billion (2018-2023)
  • Table 81. Middle East Orthobiologics, by Application USD Billion (2018-2023)
  • Table 82. Middle East Orthobiologics, by End User USD Billion (2018-2023)
  • Table 83. Africa Orthobiologics, by Type USD Billion (2018-2023)
  • Table 84. Africa Orthobiologics, by Application USD Billion (2018-2023)
  • Table 85. Africa Orthobiologics, by End User USD Billion (2018-2023)
  • Table 86. North America Orthobiologics, by Country USD Billion (2018-2023)
  • Table 87. North America Orthobiologics, by Type USD Billion (2018-2023)
  • Table 88. North America Orthobiologics, by Application USD Billion (2018-2023)
  • Table 89. North America Orthobiologics, by End User USD Billion (2018-2023)
  • Table 90. United States Orthobiologics, by Type USD Billion (2018-2023)
  • Table 91. United States Orthobiologics, by Application USD Billion (2018-2023)
  • Table 92. United States Orthobiologics, by End User USD Billion (2018-2023)
  • Table 93. Canada Orthobiologics, by Type USD Billion (2018-2023)
  • Table 94. Canada Orthobiologics, by Application USD Billion (2018-2023)
  • Table 95. Canada Orthobiologics, by End User USD Billion (2018-2023)
  • Table 96. Mexico Orthobiologics, by Type USD Billion (2018-2023)
  • Table 97. Mexico Orthobiologics, by Application USD Billion (2018-2023)
  • Table 98. Mexico Orthobiologics, by End User USD Billion (2018-2023)
  • Table 99. Orthobiologics: by Type(USD/Units)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Orthobiologics: by Type(USD Billion)
  • Table 119. Orthobiologics Viscosupplementation Products , by Region USD Billion (2025-2030)
  • Table 120. Orthobiologics DBM , by Region USD Billion (2025-2030)
  • Table 121. Orthobiologics Synthetic Orthobiologics , by Region USD Billion (2025-2030)
  • Table 122. Orthobiologics BMP , by Region USD Billion (2025-2030)
  • Table 123. Orthobiologics Allografts , by Region USD Billion (2025-2030)
  • Table 124. Orthobiologics PRP , by Region USD Billion (2025-2030)
  • Table 125. Orthobiologics BMAC , by Region USD Billion (2025-2030)
  • Table 126. Orthobiologics: by Application(USD Billion)
  • Table 127. Orthobiologics Fracture Recovery , by Region USD Billion (2025-2030)
  • Table 128. Orthobiologics Spinal Fusion , by Region USD Billion (2025-2030)
  • Table 129. Orthobiologics Soft Tissue Injuries , by Region USD Billion (2025-2030)
  • Table 130. Orthobiologics Osteoarthritis and Degenerative Arthritis , by Region USD Billion (2025-2030)
  • Table 131. Orthobiologics: by End User(USD Billion)
  • Table 132. Orthobiologics Hospitals , by Region USD Billion (2025-2030)
  • Table 133. South America Orthobiologics, by Country USD Billion (2025-2030)
  • Table 134. South America Orthobiologics, by Type USD Billion (2025-2030)
  • Table 135. South America Orthobiologics, by Application USD Billion (2025-2030)
  • Table 136. South America Orthobiologics, by End User USD Billion (2025-2030)
  • Table 137. Brazil Orthobiologics, by Type USD Billion (2025-2030)
  • Table 138. Brazil Orthobiologics, by Application USD Billion (2025-2030)
  • Table 139. Brazil Orthobiologics, by End User USD Billion (2025-2030)
  • Table 140. Argentina Orthobiologics, by Type USD Billion (2025-2030)
  • Table 141. Argentina Orthobiologics, by Application USD Billion (2025-2030)
  • Table 142. Argentina Orthobiologics, by End User USD Billion (2025-2030)
  • Table 143. Rest of South America Orthobiologics, by Type USD Billion (2025-2030)
  • Table 144. Rest of South America Orthobiologics, by Application USD Billion (2025-2030)
  • Table 145. Rest of South America Orthobiologics, by End User USD Billion (2025-2030)
  • Table 146. Asia Pacific Orthobiologics, by Country USD Billion (2025-2030)
  • Table 147. Asia Pacific Orthobiologics, by Type USD Billion (2025-2030)
  • Table 148. Asia Pacific Orthobiologics, by Application USD Billion (2025-2030)
  • Table 149. Asia Pacific Orthobiologics, by End User USD Billion (2025-2030)
  • Table 150. China Orthobiologics, by Type USD Billion (2025-2030)
  • Table 151. China Orthobiologics, by Application USD Billion (2025-2030)
  • Table 152. China Orthobiologics, by End User USD Billion (2025-2030)
  • Table 153. Japan Orthobiologics, by Type USD Billion (2025-2030)
  • Table 154. Japan Orthobiologics, by Application USD Billion (2025-2030)
  • Table 155. Japan Orthobiologics, by End User USD Billion (2025-2030)
  • Table 156. India Orthobiologics, by Type USD Billion (2025-2030)
  • Table 157. India Orthobiologics, by Application USD Billion (2025-2030)
  • Table 158. India Orthobiologics, by End User USD Billion (2025-2030)
  • Table 159. South Korea Orthobiologics, by Type USD Billion (2025-2030)
  • Table 160. South Korea Orthobiologics, by Application USD Billion (2025-2030)
  • Table 161. South Korea Orthobiologics, by End User USD Billion (2025-2030)
  • Table 162. Taiwan Orthobiologics, by Type USD Billion (2025-2030)
  • Table 163. Taiwan Orthobiologics, by Application USD Billion (2025-2030)
  • Table 164. Taiwan Orthobiologics, by End User USD Billion (2025-2030)
  • Table 165. Australia Orthobiologics, by Type USD Billion (2025-2030)
  • Table 166. Australia Orthobiologics, by Application USD Billion (2025-2030)
  • Table 167. Australia Orthobiologics, by End User USD Billion (2025-2030)
  • Table 168. Rest of Asia-Pacific Orthobiologics, by Type USD Billion (2025-2030)
  • Table 169. Rest of Asia-Pacific Orthobiologics, by Application USD Billion (2025-2030)
  • Table 170. Rest of Asia-Pacific Orthobiologics, by End User USD Billion (2025-2030)
  • Table 171. Europe Orthobiologics, by Country USD Billion (2025-2030)
  • Table 172. Europe Orthobiologics, by Type USD Billion (2025-2030)
  • Table 173. Europe Orthobiologics, by Application USD Billion (2025-2030)
  • Table 174. Europe Orthobiologics, by End User USD Billion (2025-2030)
  • Table 175. Germany Orthobiologics, by Type USD Billion (2025-2030)
  • Table 176. Germany Orthobiologics, by Application USD Billion (2025-2030)
  • Table 177. Germany Orthobiologics, by End User USD Billion (2025-2030)
  • Table 178. France Orthobiologics, by Type USD Billion (2025-2030)
  • Table 179. France Orthobiologics, by Application USD Billion (2025-2030)
  • Table 180. France Orthobiologics, by End User USD Billion (2025-2030)
  • Table 181. Italy Orthobiologics, by Type USD Billion (2025-2030)
  • Table 182. Italy Orthobiologics, by Application USD Billion (2025-2030)
  • Table 183. Italy Orthobiologics, by End User USD Billion (2025-2030)
  • Table 184. United Kingdom Orthobiologics, by Type USD Billion (2025-2030)
  • Table 185. United Kingdom Orthobiologics, by Application USD Billion (2025-2030)
  • Table 186. United Kingdom Orthobiologics, by End User USD Billion (2025-2030)
  • Table 187. Netherlands Orthobiologics, by Type USD Billion (2025-2030)
  • Table 188. Netherlands Orthobiologics, by Application USD Billion (2025-2030)
  • Table 189. Netherlands Orthobiologics, by End User USD Billion (2025-2030)
  • Table 190. Rest of Europe Orthobiologics, by Type USD Billion (2025-2030)
  • Table 191. Rest of Europe Orthobiologics, by Application USD Billion (2025-2030)
  • Table 192. Rest of Europe Orthobiologics, by End User USD Billion (2025-2030)
  • Table 193. MEA Orthobiologics, by Country USD Billion (2025-2030)
  • Table 194. MEA Orthobiologics, by Type USD Billion (2025-2030)
  • Table 195. MEA Orthobiologics, by Application USD Billion (2025-2030)
  • Table 196. MEA Orthobiologics, by End User USD Billion (2025-2030)
  • Table 197. Middle East Orthobiologics, by Type USD Billion (2025-2030)
  • Table 198. Middle East Orthobiologics, by Application USD Billion (2025-2030)
  • Table 199. Middle East Orthobiologics, by End User USD Billion (2025-2030)
  • Table 200. Africa Orthobiologics, by Type USD Billion (2025-2030)
  • Table 201. Africa Orthobiologics, by Application USD Billion (2025-2030)
  • Table 202. Africa Orthobiologics, by End User USD Billion (2025-2030)
  • Table 203. North America Orthobiologics, by Country USD Billion (2025-2030)
  • Table 204. North America Orthobiologics, by Type USD Billion (2025-2030)
  • Table 205. North America Orthobiologics, by Application USD Billion (2025-2030)
  • Table 206. North America Orthobiologics, by End User USD Billion (2025-2030)
  • Table 207. United States Orthobiologics, by Type USD Billion (2025-2030)
  • Table 208. United States Orthobiologics, by Application USD Billion (2025-2030)
  • Table 209. United States Orthobiologics, by End User USD Billion (2025-2030)
  • Table 210. Canada Orthobiologics, by Type USD Billion (2025-2030)
  • Table 211. Canada Orthobiologics, by Application USD Billion (2025-2030)
  • Table 212. Canada Orthobiologics, by End User USD Billion (2025-2030)
  • Table 213. Mexico Orthobiologics, by Type USD Billion (2025-2030)
  • Table 214. Mexico Orthobiologics, by Application USD Billion (2025-2030)
  • Table 215. Mexico Orthobiologics, by End User USD Billion (2025-2030)
  • Table 216. Orthobiologics: by Type(USD/Units)
  • Table 217. Research Programs/Design for This Report
  • Table 218. Key Data Information from Secondary Sources
  • Table 219. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Orthobiologics: by Type USD Billion (2018-2023)
  • Figure 5. Global Orthobiologics: by Application USD Billion (2018-2023)
  • Figure 6. Global Orthobiologics: by End User USD Billion (2018-2023)
  • Figure 7. South America Orthobiologics Share (%), by Country
  • Figure 8. Asia Pacific Orthobiologics Share (%), by Country
  • Figure 9. Europe Orthobiologics Share (%), by Country
  • Figure 10. MEA Orthobiologics Share (%), by Country
  • Figure 11. North America Orthobiologics Share (%), by Country
  • Figure 12. Global Orthobiologics: by Type USD/Units (2018-2023)
  • Figure 13. Global Orthobiologics share by Players 2023 (%)
  • Figure 14. Global Orthobiologics share by Players (Top 3) 2023(%)
  • Figure 15. Global Orthobiologics share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. DePuy Synthes (Johnson & Johnson) (United States) Revenue, Net Income and Gross profit
  • Figure 18. DePuy Synthes (Johnson & Johnson) (United States) Revenue: by Geography 2023
  • Figure 19. Medtronic (Ireland) Revenue, Net Income and Gross profit
  • Figure 20. Medtronic (Ireland) Revenue: by Geography 2023
  • Figure 21. Sanofi S.A (France) Revenue, Net Income and Gross profit
  • Figure 22. Sanofi S.A (France) Revenue: by Geography 2023
  • Figure 23. Stryker (United States) Revenue, Net Income and Gross profit
  • Figure 24. Stryker (United States) Revenue: by Geography 2023
  • Figure 25. Zimmer Biomet (United States) Revenue, Net Income and Gross profit
  • Figure 26. Zimmer Biomet (United States) Revenue: by Geography 2023
  • Figure 27. Alphatec Spine Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Alphatec Spine Inc. (United States) Revenue: by Geography 2023
  • Figure 29. AlloSource (United States) Revenue, Net Income and Gross profit
  • Figure 30. AlloSource (United States) Revenue: by Geography 2023
  • Figure 31. SINTX Technologies Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. SINTX Technologies Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Anika Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 34. Anika Therapeutics (United States) Revenue: by Geography 2023
  • Figure 35. Arthrex Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Arthrex Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Baxter (United States) Revenue, Net Income and Gross profit
  • Figure 38. Baxter (United States) Revenue: by Geography 2023
  • Figure 39. BBS-Bioactive Bone Substitutes (Finland) Revenue, Net Income and Gross profit
  • Figure 40. BBS-Bioactive Bone Substitutes (Finland) Revenue: by Geography 2023
  • Figure 41. Berkeley Advanced Biomaterial (United States) Revenue, Net Income and Gross profit
  • Figure 42. Berkeley Advanced Biomaterial (United States) Revenue: by Geography 2023
  • Figure 43. Wright Medical Group Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Wright Medical Group Inc. (United States) Revenue: by Geography 2023
  • Figure 45. Bioventus (United States) Revenue, Net Income and Gross profit
  • Figure 46. Bioventus (United States) Revenue: by Geography 2023
  • Figure 47. Bone Therapeutics (Belgium) Revenue, Net Income and Gross profit
  • Figure 48. Bone Therapeutics (Belgium) Revenue: by Geography 2023
  • Figure 49. Ceramisys (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 50. Ceramisys (United Kingdom) Revenue: by Geography 2023
  • Figure 51. Geistlich Bio-Oss (United States) Revenue, Net Income and Gross profit
  • Figure 52. Geistlich Bio-Oss (United States) Revenue: by Geography 2023
  • Figure 53. Global Orthobiologics: by Type USD Billion (2025-2030)
  • Figure 54. Global Orthobiologics: by Application USD Billion (2025-2030)
  • Figure 55. Global Orthobiologics: by End User USD Billion (2025-2030)
  • Figure 56. South America Orthobiologics Share (%), by Country
  • Figure 57. Asia Pacific Orthobiologics Share (%), by Country
  • Figure 58. Europe Orthobiologics Share (%), by Country
  • Figure 59. MEA Orthobiologics Share (%), by Country
  • Figure 60. North America Orthobiologics Share (%), by Country
  • Figure 61. Global Orthobiologics: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • DePuy Synthes (Johnson & Johnson) (United States)
  • Medtronic (Ireland)
  • Sanofi S.A (France)
  • Stryker (United States)
  • Zimmer Biomet (United States)
  • Alphatec Spine Inc. (United States)
  • AlloSource (United States)
  • SINTX Technologies Inc. (United States)
  • Anika Therapeutics (United States)
  • Arthrex Inc. (United States)
  • Baxter (United States)
  • BBS-Bioactive Bone Substitutes (Finland)
  • Berkeley Advanced Biomaterial (United States)
  • Wright Medical Group Inc. (United States)
  • Bioventus (United States)
  • Bone Therapeutics (Belgium)
  • Ceramisys (United Kingdom)
  • Geistlich Bio-Oss (United States)
Additional players considered in the study are as follows:
Graftys (France) , Integra Life Sciences (United States) , ISTO Technologies (United States) , NovaBone Products LLC (United States) , Orthogem (United Kingdom) , Orthofix Holdings Inc. (United States) , OsteoMed (United States) , RTI Surgical (United States) , Smith & Nephew (United Kingdom) , Xtant Medical (United States)
Select User Access Type

Key Highlights of Report


Feb 2024 241 Pages 86 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Orthobiologics Market Quantitative research analysis
Global Orthobiologics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Orthobiologics study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Orthobiologics Market is gaining popularity and expected to see strong valuation by 2030 .
According to AMA, the Global Orthobiologics market is expected to see growth rate of xx%.
The Orthobiologics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Orthobiologics Market Report?

Have a Query? Click Here

Other Related Reports

Maca Extract Comprehensive Study by Type (Raw, Gelatinized), Application (Health Drugs, Healthy Foods, Nutritional Supplements, Others), Uses (Leukemia, Chronic Fatigue Syndrome (CFS), Improving Ener...
$ 3750
Medical Tubing Comprehensive Study by Type (Polyvinyl Chloride (PVC), Thermoplastic Elastomer (TPE), Thermoplastic Polyurethane (TPU), Polyolefin, Silicone, Others), Application (Catheters & Cannulas...
$ 3750
Post-harvest Treatment Comprehensive Study by Type (Coatings, Fungicides, Cleaners, Sanitizers, Others), Treatment (Physical treatments (Heat treatment, Irradiation), Chemical treatments (Nitric oxid...
$ 3500
Next-Generation Sequencing Comprehensive Study by Type (Pre-Sequencing Products & Services, NGS Consumables, Platforms, & Services for Platforms, Sequencing Services, NGS Data Analysis, Storage, and ...
$ 3750
Low-temperature Freezers Comprehensive Study by Type (Chest, Upright, Undercounter), Application (Laboratory, Pharmaceuticals, Biobanks, Others), Body Material (Stainless Steel, Aluminum), Size (Smal...
$ 3800
Inactivated Vaccine Comprehensive Study by Type (By End User, Pediatrics, Adults, By Disease Indication, Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, MMR), Application (Hospital, M...
$ 3500